MOORE CAPITAL MANAGEMENT, LP - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 281 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.

Quarter-by-quarter ownership
MOORE CAPITAL MANAGEMENT, LP ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2022$8,384,000
-21.2%
180,185
-3.3%
0.20%
-29.9%
Q2 2022$10,634,000
+120.9%
186,306
+136.8%
0.28%
+130.3%
Q1 2022$4,814,000
+14.5%
78,668
-2.0%
0.12%
+47.0%
Q4 2021$4,203,000
+73.6%
80,300
+78.4%
0.08%
+10.7%
Q4 2015$2,421,00045,0000.08%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q4 2022
NameSharesValueWeighting ↓
DCF Advisers, LLC 359,000$18,790,0007.62%
Velan Capital Investment Management LP 150,000$7,851,0006.09%
SILVERARC CAPITAL MANAGEMENT, LLC 195,000$10,206,0004.14%
Vantage Consulting Group Inc 226,670$11,864,0003.19%
Vahanian & Associates Financial Planning Inc. 71,742$3,755,0003.03%
Nicholas Investment Partners, LP 652,886$34,172,0002.16%
COOPER/HAIMS ADVISORS, LLC 61,116$3,199,0001.97%
Bellevue Group AG 3,628,919$189,938,0001.96%
WASATCH ADVISORS LP 8,235,171$431,029,0001.76%
Quantum Private Wealth, LLC 77,622$4,062,0001.54%
View complete list of INTRA CELLULAR THERAPIES INC shareholders